Grifols has introduced its direct-to-consumer programme, AlphaID At Home Genetic Health Risk Service (AlphaID At Home), in the US.

The new programme will help screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1), which is also called genetic chronic obstructive pulmonary disease.

In November 2022, the US Food and Drug Administration (FDA) approved AlphaID At Home for direct-to-consumer use.

The test can screen for the most prevalently reported genetic mutations linked to alpha-1, including the S, Z, F and I alleles, as well as rare and null alleles.

It utilises the same precise genotyping test manufactured by the company and provided to physicians worldwide since 2018 for alpha-1 screening.

Grifols Diagnostic president Antonio Martínez said: “Given the fact that it can take several years until a patient with alpha-1 is properly diagnosed, AlphaID At Home can indicate someone’s risk for alpha-1 in a matter of weeks.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AlphaID At Home is now accessible for ordering in the US at no cost via a secure online portal that complies with HIPAA standards.

After receiving the at-home screening kit, individuals can easily collect their saliva sample and send it to a laboratory adhering to the Clinical Laboratory Improvement Amendments standards for further processing.

Individuals can access their genetic results through a secure online portal after a few weeks.

Alpha-1 Foundation president and CEO Scott Santarella said: “We wholeheartedly support initiatives and innovations that contribute to the diagnosis of alpha-1. As leaders in alpha-1 testing, Grifols is doubling down on its commitment to the alpha-1 community by making it easier and more efficient to get diagnosed.”